Table 3.
Univariate and multivariate Cox analyses including the risk group and other molecular annotations.
| Variables | Univariate Analysis | Best Multivariate Model | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Value | HR | 95%C.I. | Modality | Model | HR | 95%C.I. | modality | model | |
| p Value | p Value | p Value | p Value | ||||||
| (Wald) | (Log-Rank) | (Wald) | (Log-Rank) | ||||||
| Tumor stage (ref = I and II) | III and IV | 4.69 | 2.84–7.75 | 1.48 × 10−9 | 3.00 × 10−11 | 3.47 | 2.06–5.84 | 2.80 × 10−6 | <2.00 × 10−16 |
| Age | — | 1.04 | 1.02–1.06 | 2.25 × 10−5 | 2.00 × 10−5 | 1.04 | 1.02–1.07 | 3.62 × 10−5 | |
| Risk group (Ref = low risk) | High risk | 5.15 | 2.81–9.45 | 1.17 × 10−7 | 4.00 × 10−9 | 3.92 | 2.08–7.38 | 2.25 × 10−5 | |
| Non-silent mutations in VHL (ref = No) | Yes | 0.77 | 0.48–1.23 | 0.28 | 0.3 | 0.68 | 0.43–1.10 | 0.11 | |
| Non-silent mutations in PBRM1 (ref = No) | Yes | 0.83 | 0.51–1.34 | 0.44 | 0.4 | ||||
| Non-silent mutations in TTN (ref = No) | Yes | 1.24 | 0.70–2.21 | 0.46 | 0.5 | ||||
| Non-silent mutations in SETD2 (ref = No) | Yes | 1.44 | 0.77–2.69 | 0.25 | 0.2 | ||||
| Non-silent mutations in BAP1 (ref = No) | Yes | 2.05 | 1.15–3.65 | 0.01 | 0.01 | ||||
| Sex (ref = Female) | Male | 0.75 | 0.47–1.20 | 0.22 | 0.2 | ||||
HR, Cox hazard ratio; 95% C.I., 95% confidence interval of the HR; Value, modality of the annotation associated with the HR; ref, reference.